Tag Archives: PARTNER 3 Low Risk

TCT 2023 | ALIGN AR trial

TCT 2023 | PARTNER 3 Low Risk: 5-Year Follwup

TCT 2023 | PARTNER 3 Low Risk: 5-Year Follwup

TCT has presented the 5-year clinical and echocardiographic outcomes of low-risk patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR) using balloon-expandable Sapien valves vs. surgical aortic valve replacement (SAVR).  The first primary end point was a non-hierarchical composite of all-cause mortality stroke or rehospitalization. The second was a hierarchical composite including

Top